2025年,特朗普的行政命令将大麻重新分类为附表三,促进联邦医学研究,并有利于MMJ国际控股公司等公司。 In 2025, Trump's executive order reclassified cannabis to Schedule III, boosting federal medical research and favoring companies like MMJ International Holdings.

2026年3月,特朗普总统的2025年行政命令加速联邦将大麻重新分类为附表三,承认大麻在医疗方面的公认用途,并将重点转向临床发展而不是零售。 In March 2026, President Trump’s 2025 executive order accelerated the federal reclassification of cannabis to Schedule III, recognizing its accepted medical use and shifting focus to clinical development over retail sales. 这一变化加强了联邦监督,有利于MMJ国际控股公司等公司,这些公司持有活跃的林业发展局调查性新药物应用以及神经疾病孤儿药品标识。 This change strengthens federal oversight and favors companies like MMJ International Holdings, which holds active FDA Investigational New Drug applications and Orphan Drug Designations for neurological conditions. MMJ国际控股公司是为满足联邦药物开发标准而建立的,拥有标准化的软凝胶配方和全球合规性,在新兴制药大麻素领域处于领先地位。 MMJ International Holdings, built to meet federal drug development standards with standardized soft-gel formulations and global compliance, is positioned as a leader in the emerging pharmaceutical cannabinoid landscape. 这一转变反映了以科学为基础的监管和国际协调的大趋势,将投资引向联邦一体化、研究驱动的公司,而不是以国家为重点的零售商。 The shift reflects a broader trend toward science-based regulation and international harmonization, directing investment toward federally integrated, research-driven firms rather than state-focused retailers.